Section Arrow
Quote
KALV.NASDAQ
- KalVista Pharmaceuticals
Quotes are at least 15-min delayed:2026/03/09 16:37 EDT
After Hours
Last
 17.35
+0.05 (+0.29%)
Bid
16
Ask
17.92
High 17.92 
Low 17.3 
Volume 13.40K 
Regular Hours (Closed)
Last
 17.3
+1.127 (+6.97%)
Day High 
18.16 
Prev. Close
16.173 
1-M High
16.75 
Volume 
291 
Bid
16
Ask
17.92
Day Low
16.08 
Open
16.08 
1-M Low
14.225 
Market Cap 
817.49M 
Currency 美元 
P/E -- 
%Yield 2.05 
10-SMA 15.96 
20-SMA 15.6 
50-SMA 15.59 
52-W High 19 
52-W Low 9.235 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.94/0.82
Enterprise Value
821.82M
Balance Sheet
Book Value Per Share
0.34
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ANTXAN2 Therapeutics5.25+2.41+84.86%-- 
After Hours 5.1352 -0.1148 -2.19%
RLMDRelmada Therapeutics7.17+2.72+61.12%-- 
After Hours 6.85 -0.32 -4.46%
IOVAIovance Biotherapeutics5.41+0.275+5.36%-- 
After Hours 5.37 -0.04 -0.74%
IBRXImmunityBio8.45-0.2-2.31%-- 
After Hours 8.4391 -0.0109 -0.13%
QNCXQuince Therapeutics0.1065+0.0042+4.11%-- 
After Hours 0.1044 -0.0021 -1.97%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.